Treatment of -mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.
Study question Can a low‑intensity, once‑weekly “metronomic” regimen of decitabine plus venetoclax provide mea...
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This single-center retrospective study evaluated outcomes of allogeneic stem cell transplantation in 2045 patients with...
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This study evaluated how specific genetic lesions add to MRD-based risk stratification in adult core-binding factor (CBF...
Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This retrospective study used the Hokkaido Leukemia Net database to examine how the approval of venetoclax changed real-...
Thrombotic and Bleeding Complications in Myeloproliferative Neoplasms: An Integrated Clinical Perspective.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This review article focuses on thrombotic and bleeding complications in myeloproliferative neoplasms (MPNs) and their im...
Predictive capacity of peritransplant measurable residual disease thresholds in NPM1-mutant acute myeloid leukemia.
- Post category:Hematologic Cancers
- Reading time:2 mins read
This retrospective two-center study evaluated how quantitative NPM1-mutated MRD levels around allogeneic transplant pred...